IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科
学科主题临床医学
Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine
Guo, Zhongqiang1; Zhang, Xiaoyu1; Li, Xuesong1; Xie, Feng1; Su, Boxing1; Zhang, Min1; Zhou, Liqun1,2
关键词Prostate Cancer Hmgn5 Gemcitabine Biomarker Mapk Pathway
刊名ONCOLOGY REPORTS
2015-03-01
DOI10.3892/or.2014.3696
33期:3页:1519-1525
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
资助者National Natural Science Foundation of China ; Beijing National Science Foundation of China ; National Natural Science Foundation of China ; Beijing National Science Foundation of China
研究领域[WOS]Oncology
关键词[WOS]NUCLEOSOMAL BINDING-PROTEIN ; PHASE-II TRIAL ; CARCINOMA-CELLS ; IN-VITRO ; TRANSCRIPTION ; VARIANTS ; RECEPTOR ; GROWTH ; NSBP1 ; GENE
英文摘要

Prostate cancer is a leading cause of cancer-related death among men. Early diagnosis and treatment are successful against prostate cancer, yet the clinical treatment of advanced prostate cancer remains a challenge. Gemcitabine is used to treat a broad spectrum of solid tumors; however, the clinical response of prostate cancer patients to gemcitabine is limited. In the present study, we showed that HMGN5, a nucleosome binding protein that can unfold chromatin by binding to histone (H1), is overexpressed in prostate cancer cells and plays an oncogenic role in prostate cancer tumorigenesis and development by activating the MAPK signaling pathway. We also found that sensitivity of prostate cancer cells to gemcitabine was positively correlated with HMGN5 expression. Knockdown of HMGN5 expression reduced the sensitivity of PC-3 cells to gemcitabine, and ectopic HMGN5 expression in DU145 cells enhanced the sensitivity to gemcitabine. Gemcitabine decreased HMGN5 expression, consequently leading to inactivation of the MAPK signaling pathway and cleavage of the PARP protein. Finally, we showed that PC-3 cells acquire gemcitabine resistance by gradual loss of HMGN5 expression. The present study suggests that HMGN5 is a potential biomarker for treating prostate cancer, and patients with a high level HMGN5 will benefit from gemcitabine treatment.

语种英语
所属项目编号30672099 ; 7122183
资助者National Natural Science Foundation of China ; Beijing National Science Foundation of China ; National Natural Science Foundation of China ; Beijing National Science Foundation of China
WOS记录号WOS:000349735800065
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52277
专题北京大学第一临床医学院_泌尿外科
作者单位1.Peking Univ, Hosp 1, Dept Urol, Beijing 100034, Peoples R China
2.Peking Univ, Inst Urol, Beijing 100034, Peoples R China
推荐引用方式
GB/T 7714
Guo, Zhongqiang,Zhang, Xiaoyu,Li, Xuesong,et al. Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine[J]. ONCOLOGY REPORTS,2015,33(3):1519-1525.
APA Guo, Zhongqiang.,Zhang, Xiaoyu.,Li, Xuesong.,Xie, Feng.,Su, Boxing.,...&Zhou, Liqun.(2015).Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.ONCOLOGY REPORTS,33(3),1519-1525.
MLA Guo, Zhongqiang,et al."Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine".ONCOLOGY REPORTS 33.3(2015):1519-1525.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Guo, Zhongqiang]的文章
[Zhang, Xiaoyu]的文章
[Li, Xuesong]的文章
百度学术
百度学术中相似的文章
[Guo, Zhongqiang]的文章
[Zhang, Xiaoyu]的文章
[Li, Xuesong]的文章
必应学术
必应学术中相似的文章
[Guo, Zhongqiang]的文章
[Zhang, Xiaoyu]的文章
[Li, Xuesong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。